Loading
Sequencing the unique genetic barcode of a patient's leukaemia to find one cancer cell in a million.
clonoSEQ (Adaptive Biotechnologies) tracks clonal IGH/TCR rearrangements at 10^-6 and is FDA-cleared for ALL, myeloma, and CLL. In AML, quantitative PCR of NPM1 or core-binding-factor fusion transcripts and error-corrected NGS of persistent mutations (excluding DNMT3A/TET2/ASXL1) define molecular MRD per ELN 2021. MRD status now drives transplant decisions in AML, blinatumomab use in ALL, and fixed-duration versus continuous therapy debates in CLL.
The assay deep-sequences a patient-specific clonotype or mutation with error correction.
A DNA test that counts leftover leukaemia, myeloma or lymphoma cells down to one in a million, used to decide whether treatment has really worked.
Query for this technology: (TITLE:"NGS-based MRD" OR ABSTRACT:"NGS-based MRD" OR TITLE:"clonoSEQ and molecular MRD" OR ABSTRACT:"clonoSEQ and molecular MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NGS-based MRD (clonoSEQ and molecular MRD), not a curated reading list.
Shares B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status), Acute lymphoblastic leukaemia and the tag precision.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag precision.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag precision.
Shares MRD / molecular residual disease testing and the tag precision.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag precision.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag precision.
Shares myeloMATCH, Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL), Mantle cell lymphoma, Acute myeloid leukaemia and the tag precision.
Shares Reference materials and open proficiency testing for residual disease tests, Watch the immune system's response in the blood three weeks in, Dormant cells and minimal residual disease, MRD / molecular residual disease testing and the tag precision.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/